ICC International Cannabis Corp. announced that the Company, alongside Biotii Technologies Corp. has entered into a design and automation agreement with Y Combinator backed Opentrons Labworks Inc. The Companies will collaborate to architect and construct Canada’ first privately owned high-throughput Bioworks Foundry. The Bioworks Foundry will function as a staging ground for Biotii’s cannabinoid researchers and organism designers to manufacture and analyze prototype enzyme pathways. The facility will afford International Cannabis and Biotii the ability to scale its synthesized cannabinoid testing processes in a rapid and cost effective fashion, by leveraging: Advanced DNA assembly protocols; Laboratory automation; and, High performance analytics. The completion of the Companies’ high-throughput Bioworks Foundry will catapult Biotii into an elite consortium of less than 20 laboratories worldwide equipped with the ability to automate genome assembly of multiple DNA fragments. Opentrons’ OT-2 Robot (the “OT-2”) will provide Biotii with unbridled access to a proven molecular biology platform, furnished with hundreds of existing protocols and over 5,400 software commits from a diverse community of researchers; including leading teams from Stanford University and the Mayo Clinic. Bolstered by the continued financial backing of ICC, coupled with the integration Opentrons’ advanced operational/engineering frameworks into the planned Bioworks Foundry, the Biotii team remains steadfast to its 2020 mandate cannabinoid production in quantities of hundreds of metric tonnes per annum, boasting: Stable and consistent yields; Pharmaceutical-grade purities; and, Lowest production costs in the space. Opentrons platform affords Biotii access to the initial technology and laboratory infrastructure necessary for the architecture of its automated, high-throughput Bioworks Foundry. It is anticipated that the Bioworks Foundry will accelerate the Companies’ cannabinoid research and development capabilities, thereby capturing significant IP within the fast-developing biosynthesis market for cannabinoids. The OT-2 will also enable Biotii to customize laboratory automation for maximum leverage of engineering talent. The extensive library of standard protocols developed for the OT-2 provides a foundation upon which can build a comprehensive automated pipeline from plasmid prep, to transfection, fermentation, and to target molecule samples.